Brief: Ortho Regenerative Technologies Receives Clinical Hold Letter From The U.S. FDA
04/06/2021 12:17
June 4 (Reuters) - Ortho Regenerative Technologies Inc
ORTH.CD :
* ORTHO REGENERATIVE TECHNOLOGIES RECEIVES CLINICAL HOLD
LETTER
FROM THE U.S. FDA
* ORTHO REGENERATIVE TECHNOLOGIES INC - ADDITIONAL CMC
RELATED
DATA AND CHARACTERIZATION REQUESTED BY FDA
* ORTHO REGENERATIVE TECHNOLOGIES INC - PHASE I/II CLINICAL
TRIAL
PREPARATION ACTIVITIES TO CONTINUE IN PREPARATION OF ANTICIPATED
IND APPROVAL
Source text for Eikon: ID:nCNWY1PnRa
Further company coverage: ORTH.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chitogenx
See all newsBrief: Chitogenx Announces Signing Of Binding Letter Of Intent With Oligo Medic
Brief: Chitogenx Announces Executive Leadership Changes
Brief: Chitogenx Inc - Study Results To Be Available Q3-24 After Mandatory Post-Surgery Monitoring
Brief: Chitogenx Concludes Enrolment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Brief: Chitogenx Announces New $2.5 Million Non-Brokered Private Placement Offering And Balance Sheet Restructuring